Announced Date: 2025-06-26 (June 26, 2025) Asset Name: 9MW3811 Licensor: Mabwell (Shanghai) Bioscience (China) Licensee (Buyer): … [China BD 2025] Mabwell Bioscience and Calico Life Sciences Enters a 596 million USD License for IL-11 Targeting Monoclonal Antibody 9MW3811Read more
[China BD 2025] Harbour BioMed and Otsuka enters a 670 million USD License on BCMAxCD3 bispecific T-cell engager HBM7020
Announced Date: 2025-06-22 (June 22, 2025) Asset Name: HBM7020 Licensor (Seller): Harbour BioMed (China) Licensee (Buyer): … [China BD 2025] Harbour BioMed and Otsuka enters a 670 million USD License on BCMAxCD3 bispecific T-cell engager HBM7020Read more
[Technology Collaboration] CSPC and AstraZeneca enters a 5.3 billion USD Collaboration on AI-enabled drug research
Announced Date: 2025-06-13 (June 13, 2025) Licensor: CSPC (CSPC Pharmaceuticals Group Limited. , China) Licensee: AstraZeneca（UK） Collaboration … [Technology Collaboration] CSPC and AstraZeneca enters a 5.3 billion USD Collaboration on AI-enabled drug researchRead more
[China BD 2025] Intragrand and Transpire enters a license on PDE4 inhibitor ITG-1052
Announced Date: 2025-06-03 (June 3, 2025) Asset Name: ITG-1052 (Lenamilast) Licensor: Suzhou Intragrand Pharma (China) Licensee … [China BD 2025] Intragrand and Transpire enters a license on PDE4 inhibitor ITG-1052Read more
[China Original Asset] BioNTech and BMS enters a 11.1 billion USD Collaboration on PD-L1xVEGF-A BsAbs BNT327 (PM8002 from Biotheus)
Announced Date: 2025-06-02 (June 2, 2025) Asset Name: BNT327 (PM8002 from Biotheus) Licensor: Biopharmaceutical New Technologies … [China Original Asset] BioNTech and BMS enters a 11.1 billion USD Collaboration on PD-L1xVEGF-A BsAbs BNT327 (PM8002 from Biotheus)Read more
[China BD deal 2025]Hansoh and Regeneron enters a 2 billion USD license on GLP-1/GIP Ra HS-20094
Announced Date: 2025-06-02 (June 2, 2024) Asset Name: HS-20094 Licensor: Hansoh (Hansoh Pharmaceuticals Group, China) Licensee … [China BD deal 2025]Hansoh and Regeneron enters a 2 billion USD license on GLP-1/GIP Ra HS-20094Read more
[China BD 2025] Evopoint and Astellas enters a 1.54 billion USD license on CLDN18.2 ADC XNW27011
Announced Date: 2025-05-29 (May 29, 2025) Asset Name: XNW27011 Licensor: Evopoint (Evopoint Biosciences Co., Ltd., China) Licensee … [China BD 2025] Evopoint and Astellas enters a 1.54 billion USD license on CLDN18.2 ADC XNW27011Read more
[China FIC Drug] Influenza A virus RNA Polymerase PB2 Inhibitor First in Class Drug Onradivir Approved by China NMPA in 2025
Drug Name: Onradivir Drug Modality: Small Molecule Drug Target: Influenza A virus RNA Polymerase PB2 Inhibitor Developed By：Guangdong Raynovent Biotech … [China FIC Drug] Influenza A virus RNA Polymerase PB2 Inhibitor First in Class Drug Onradivir Approved by China NMPA in 2025Read more
[China BD 2025] Qyuns and Caldera Entered a License for Bispecific Antibody QX030N
Announced Date: 2025-04-23 (April 23, 2025) Asset Name: QX030N Licensor (Seller): Qyuns Therapeutics (China) Licensee (Buyer): … [China BD 2025] Qyuns and Caldera Entered a License for Bispecific Antibody QX030NRead more
[China BD 2025] VelaVigo and Ollin Biosciences Enters a 440 million USD License on IGF-1R/TSHR BsAbs VBS-102
Announced Date: 2025-04-18 (April 18, 2025) Asset Name: VBS-102 Licensor: VelaVigo Bio (China) Licensee (Buyer): Ollin … [China BD 2025] VelaVigo and Ollin Biosciences Enters a 440 million USD License on IGF-1R/TSHR BsAbs VBS-102Read more